Concurrent 5-fluorouracil, mitomycin C and radiation, with or without brachytherapy, in recurrent endometrial cancer: A scoring system to predict clinical response and outcome

Tumori

Volumn 91, Issue 3, 2005, Pages 215-220

  Smaniotto, Daniela ^a   D'Agostino, Giuseppe ^a   Luzi, Stefano ^a   Valentini, Vincenzo ^a   Macchia, Gabriella ^a   Mangiacotti, Maria Grazia ^a   Margariti, Pasquale Alessandro ^a   Ferrandina, Gabriella ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chemoradiation; Endometrial cancer; Local recurrence; Prognostic score

Indexed keywords

FLUOROURACIL; HEMOGLOBIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; BEAM THERAPY; BLOOD TOXICITY; BRACHYTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; ENDOMETRIUM CANCER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LYMPH NODE; PROGNOSIS; RADIATION DOSE; RECURRENT CANCER; SCORING SYSTEM; STENOSIS; TIME; VAGINA DISEASE;

EID: 23044504953     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100301     Document Type: Article

References (33)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics 2004. Cancer J Clin, 54: 8-29, 2004.
2. Elit L, Hirte H: Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol, 14: 67-73, 2002.
3. Koh W, Tran AB, Douglas JG, Stelzer KJ: Radiation therapy in endometrial cancer. Best Pract Res Clin Obstet Gynecol, 15: 417-432, 2001.
4. Irvin WP, Rice LW: Advances in the management of endometrial adenocarcinoma. J Reprod Med, 47: 173-190, 2002.
5. Cohen EEW, Lingen MW, Vokes EE: The expanding role of systemic therapy in head and neck cancer. J Clin Oncol, 22: 1743-1752, 2004.
6. Thomas GM: Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy. N Engl J Med, 340: 1198-1199, 1999.
7. Englemann MA, Small W: Combined modality therapy in the treatment of gynecologic malignancies. Semin Oncol, 30 (S9): 80-94, 2003.
8. Nigro ND, Vaitnevicius VK, Considine B: Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum, 17: 354-356, 1974.
9. Haghbin M, Sischy B, Hinson J: Combined modality preoperative therapy in poor prognostic rectal adenocarcinoma. Radiother Oncol, 13: 75-81, 1988.
10. Wong CS, Cummings BJ, Keane TJ, Dobrowsky W, O'Sullivan MB, Catton CN: Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys, 21: 1291-1296, 1991.
11. Radiation Therapy Oncology Group morbidity scoring criteria. www.rtog.org/members/toxicity/main.html
12. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
13. Kaplan FL, Meier P: Non parametric estimation from incomplete observations. Am J Stat Assoc, 53: 457-481, 1958.
14. Peto R, Peto J: Asymptomatically efficient rank invariant procedures. J R Stat Soc, 135: 185-207, 1972.
15. Cox DR: Regression model and life tables. J Royal Stat Soc, 34: 187-220, 1972.
16. Elit L, Hirte H: Novel strategies for systemic treatment of endometrial cancer. Exp Opin Invest Drugs, 9: 1-23, 2000.
17. Morrow CP, Bundy BN, Homesley HD: Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study. Gynecol Oncol, 36: 166-171, 1990.
18. Sears JD, Greven KM, Hoen HM, Randall ME: Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer, 74: 1303-1308, 1994.
19. Hart KB, Han I, Shamsa F, Court WS, Chuba P, Deppe G, Malone J, Christensen C, Porter AT: Radiation therapy for endometrial cancer in patients treated for postoperative recurrence. Int J Radiat Oncol Biol Phys, 41: 7-11, 1998.
20. Jereczek-Fossa B, Badzio A, Jassem J: Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys, 48: 405-413, 2000.
21. Wylie J, Irwin C, Pintilie M, Levin W, Manchul L, Milosevic M, Fyles A: Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol, 77: 66-72, 2000.
22. Million RR, Zimmerman RC: Evaluation of University of Florida split-course technique for various head and beck squamous cell carcinomas. Cancer, 35: 1533-1536, 1975.
23. Budihna M, Skrk J, Smid L, Furlan L: Tumor cell repopulation in the rest interval of split-course radiation treatment. Strahlenther Onkol, 156: 402-408, 1980.
24. Cummings BJ, Keane TJ, O'Sullivan MB, Wong CS, Catton CN: Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys, 21: 1115-1125, 1991.
25. Smaniotto D, Luzi S, Morganti AG, Cellini N: Prognostic significance of anemia and role of erythropoietin in radiation therapy. Tumori, 86: 17-23, 2000.
26. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol, 13: 2077-2083, 1995.
27. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset JM: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology, 201: 553-558, 1996.
28. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer, 86: 1528-1536, 1999.
29. Salvesen HB, Iversen OE, Akslen LA: Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol, 17: 1382-1390, 1999.
30. Fiumicino S, Ercoli A, Ferrandina G, Hess P, Raspaglio G, Genuardi M, Rovella V, Bellacosa A, Cicchillitti L, Mancuso S, Bignami M, Scambia G: Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J Clin Oncol, 19: 1008-1014, 2001.
31. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, Mancuso S, Scambia G, Lauriola L: Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer, 95: 801-807, 2002.
32. Randall ME, Spirtos NM, Dvoretsky P: Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr, 19: 13-15, 1995.
33. Curran WJ: New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology, 63: 29-38, 2002.